University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial SWOG-S1211


A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High-Risk Multiple Myeloma (HRMM).

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic, Immunomodulator, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Kevin Kelly, M.D.
Other Trial Staff:  Christine Duran, D.M., Melissa Peralta, D.M., Sondra Ortiz, R.N., Teresa Olea, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.